These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 11105596

  • 1. [Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies].
    Belaiche J, Louis E.
    Rev Med Liege; 2000 Sep; 55(9):827-32. PubMed ID: 11105596
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD.
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [Abstract] [Full Text] [Related]

  • 3. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease.
    Mouser JF, Hyams JS.
    Clin Ther; 1999 Jun; 21(6):932-42; discussion 931. PubMed ID: 10440618
    [Abstract] [Full Text] [Related]

  • 4. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [Abstract] [Full Text] [Related]

  • 5. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 7. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
    Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z.
    Dig Dis; 2006 May; 24(1-2):201-6. PubMed ID: 16699279
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 11. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 14. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR.
    Ital J Gastroenterol Hepatol; 1999 Sep; 31(6):519-20. PubMed ID: 10575573
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
    Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T.
    J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 17. Anti-TNF alpha: new therapy for Crohn's disease.
    Mikula CA.
    Gastroenterol Nurs; 1999 Jul; 22(6):245-8. PubMed ID: 10855120
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I, Yeshurun D, Hallak A, Horowitz N, Tiomny E, Reif S, Halpern Z, Rachmilewitz D.
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [Abstract] [Full Text] [Related]

  • 19. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 20. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM, Krauss N, Voll RE, Nägel A, Weidenhiller M, Konturek PC, Hahn EG, Raithel M.
    Digestion; 2008 Feb 13; 78(4):195-200. PubMed ID: 19122456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.